Show simple item record

Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data

dc.contributor.authorFalchi, L.en
dc.contributor.authorClausen, M.en
dc.contributor.authorOffner, F.en
dc.contributor.authorDe Vos, S.en
dc.contributor.authorBrody, J.en
dc.contributor.authorLinton, Kim Men
dc.contributor.authorSnauwaert, S.en
dc.contributor.authorCordoba, R.en
dc.contributor.authorWu, J.en
dc.contributor.authorBykhovski, I.en
dc.contributor.authorWang, L.en
dc.contributor.authorRana, A.en
dc.contributor.authorBelada, D.en
dc.date.accessioned2023-10-25T08:48:36Z
dc.date.available2023-10-25T08:48:36Z
dc.date.issued2023en
dc.identifier.citationFalchi L, Clausen M, Offner F, De Vos S, Brody J, Linton KM, et al. Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003462.en
dc.identifier.doi10.1200/JCO.2023.41.16_suppl.7519en
dc.identifier.urihttp://hdl.handle.net/10541/626651
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2023.41.16_suppl.7519en
dc.titleMetabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 dataen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentLymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NYen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record